Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.41 |
| ▸ | PIK3C2B | O00750 | 3/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488571 | 0.89 | PDE2A (0.36) | DCTPP1PIK3C2B | |
| SCHEMBL6490645 | 0.86 | PTGDR (0.44) | DCTPP1PIK3C2BRXRARXRBPPARG | |
| SCHEMBL6496733 | 0.86 | ALOX5AP (0.47) | DCTPP1PIK3C2BRXRARXRBPPARG | |
| SCHEMBL6489563 | 0.86 | SMN1; SMN2 (0.52) | DCTPP1PIK3C2BRXRARXRBPPARG | |
| SCHEMBL6488579 | 0.86 | PPARG (0.46) | RXRARXRBPPARGALOX5APEIF4EBP1 | |
| SCHEMBL6488966 | 0.82 | RXRA (0.41) | DCTPP1PIK3C2BRXRARXRBPPARG | |
| SCHEMBL6498192 | 0.80 | RXRA (0.43) | RXRARXRBPPARGNPC1RAB9A | |
| SCHEMBL6497678 | 0.80 | PTPN11 (0.46) | PPARGEIF4EBP1 | |
| SCHEMBL6487328 | 0.79 | RXRA (0.40) | DCTPP1RXRARXRBPPARGSLC22A12 | |
| SCHEMBL6498502 | 0.79 | ALOX5AP (0.37) | DCTPP1PIK3C2BPPARGNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | DCTPP1 1534/4885PIK3C2B 2433/4885RXRA 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.